

**Cancer Care Ontario**

**Action Cancer Ontario**

# **The Mystery of Ontario's Unusually High Pancreatic Cancer Survival**

**Diane Nishri**

**Cancer Care Ontario, Toronto, Ontario**

# Outline

- The mystery & the clues
- The suspect & the evidence
- A possible solution
- Conclusions and further sleuthing

# The mystery

- C-SPAN (Cancer survival & prevalence analytic network) calculated survival for major cancers using the CCR:
  - Ages 15-44, 45-54, 55-65, 65-74, 75-99
  - Diagnosis years 1992-94, 1995-97, 1998-2000, 2001-2003\*, 2004-2007\*
  - Province, Sex (where possible)
  - 1, 3, 5, & 10 year relative survival

# The mystery

- For most estimates, Ontario's survival were similar to those from other provinces
- For pancreatic cancer, Ontario's survival was unusually high
  - 2004-07, 5-year age-standardized period relative survival estimate: Ontario, 10.2; other provinces, 3.4 to 5.9

# The clues

- Age group, diagnosis period and time since diagnosis were examined to determine, if possible, how Ontario's survival differs from the other provinces.
- Ontario's survival was different for:
  - 15-44, 1-year, all periods
  - 65-74 & 75-99, 3- & 5-year, all periods
  - 2001-3 & 2004-7 periods, 3-year, all ages<sub>5</sub>

# Data quality suspect #1

- Incorrect inclusion/exclusion of cases
  - If residence is missing, include
  - ON's conservative multiple primary rules
  - Too many surgery without pathology cases; maybe not really cancer?
  - Autopsy only and death certificate only cases routinely excluded from survival analyses

# Data quality suspect #2

- Bias in determination of diagnosis date
  - Hall et al, 2006, compared head and neck cases from the OCR to a clinical series and found that diagnosis dates in the OCR were significantly earlier
  - This can also occur when two primaries are resolved as one.

# Data quality suspect #3

- Bias in determination of vital status
  - National death clearance does not include Quebec
  - Can not use the provincial health insurance file to censor those who emigrate from the province



# These issues overlap!

- Example: Death certificate only
  - Incident case may have been diagnosed elsewhere
  - No match to case due to linkage failure
  - Date of diagnosis unknown, but survival tends to be short
  - Cause of death may be inaccurate (Hall et al, cause of death had 31% error rate)

# Follow the Evidence!




# The culprit: lost to follow-up

- Ontario uses only passive registration methods
  - Relies on linkages to mortality data or reports from treatment clinics and hospitals for vital status and date of death
- Usual assumption: cases lost to follow-up are alive at the end of the study

# Ontario pancreas data

- 12,379 cases diagnosed 1992-2003
- Followed to December 31, 2008
- Excludes
  - 700 DCO cases (5.3%)
  - 7 Autopsy only cases
  - 26 cases with missing residence

# Sample survival data




$$\% \text{ Lost} = 8/35 \\ = 22.9\%$$

$$\% \text{ Alive} = 10/27 \\ = 37.0\%$$

- Finnish colon cases (Dickman & Lambert)


# Follow-up & survival: sex

Percent




# Microscopic confirmation

Percent



# Surgery


Percent






# Diagnosis period

Percent




# Beale code

Percent




# Age group

Percent



# Median observed time

Months



# Paper #1

- Brenner & Hakulinen (2009)
- Finnish Cancer Registry, 20 common cancers, dx 1985-9, follow-up 2004
- Under-ascertainment of deaths:
  - Imperfect death linkage, 0.1-5%
  - Unregistered emigration, 0.05-2%

# Paper #1 Results

- “Even modest levels of under-registration of deaths may lead to severe overestimation of long-term survival estimates”
- Worse for
  - Relative survival
  - Older ages
  - Unrecorded emigration

# Paper #2

- Johnson, Weir, Yin & Niu (2010)
- SEER data, SEER site recode, dx 1995-2000, follow-up 2005
- Characteristics of synthetic datasets:
  - Incomplete death ascertainment: 2%-10%
  - Follow-up of live patients: none, or incomplete (5%-30%)

# Paper #2 Results

- When death ascertainment is *complete*
  - Minor differences with no follow-up
  - As loss increases, survival estimates decrease
  - Impact greatest for cancers with very high or very low case fatality rates



# Paper #2 Results

- When death ascertainment is *incomplete*
  - Missing even a small proportion of deaths resulted in high survival
  - Impact of missing deaths most evident for cancers with high fatality rates


# What's up with ON?

- Large, growing immigrant population
  - Return to homeland after diagnosis?
- No alternate sources for residence/vital status verification
- Incomplete national death clearance

# Loss-adjusted survival

- “Cancer survival in Africa, Asia, the Caribbean and Central America”, IARC 2011. (Chapter 2, Ganesh et al)
- Estimated by assuming that survival of patients lost to follow-up is the same as that for patients with known follow-up and similar prognostic factors.

# Observed 5-year survival



# Conclusions

- The assumption that cases lost to follow-up are alive at the cut-off date appears to be responsible for the bias in Ontario's high pancreatic cancer survival
- The impact of emigration may be greater than expected elsewhere
- Additional linkages should be considered to improve follow-up

# Next steps

- Loss correction:
  - Adjust for multiple prognostic factors
  - Explore relative survival and period method
  - Analyze other cancers, especially lung, liver and melanoma
- Further explore the DCOs

# References

- Hall S et al. “Using cancer registry data for survival studies: the example of the Ontario Cancer Registry”, *J Clin Epi* 59 (2006): 67-76.
- Brenner H and Hakulinen T. “Implications of incomplete registration of deaths on long-term survival estimates from population-based cancer registries.” *Int J Cancer* 125.2 (2009): 432-37.
- Johnson CJ, Weir HK, Hin D, Niu X. “The impact of patient follow-up of population-based survival rates”, *J Registry Management* 37.3 (2010): 86-103.
- Sankaranarayanan R, Swaminathan R, Lucas E. Cancer survival in Africa, Asia, the Caribbean and Central America (SurvCan). IARC Scientific Publications volume 162, ISBN 978-92-832-2162-3, Lyon, International Agency for Research on Cancer (2011).